How did the Pro Medicus (ASX:PME) share price respond last earnings season?

Pro Medicus' FY21 earnings are imminent. While we wait, let's take a look at how its shares reacted to its FY20 results

| More on:
Three healthcare workers look and point at at medical image

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price has had a brilliant 12 months on the ASX, and all eyes will be on it tomorrow when the company drops its results for financial year 2021 (FY21).

Since this time last year, the Pro Medicus share price has gained a whopping 136%. For comparison, the S&P/ASX 200 Index (ASX: XJO) increased 24% in the same time frame. However, Pro Medicus shares have dipped by 0.12% in early trade today.

Market watchers will likely be particularly curious about Pro Medicus' earnings since the company's stock hit its highest closing price of all time just over a month ago.

So, as the market awaits the healthcare imaging company's FY21 earnings, lets cast our minds back to its FY20 results and how the Pro Medicus share price reacted.

How did Pro Medicus perform in FY20?

The market wasn't excited about Pro Medicus' FY20 earnings, despite the company's performance being relatively strong. Here's a sample of Pro Medicus' FY20 results:

  • $56.8 million of revenue from underlying operations, 23.9% more than the prior corresponding period
  • Underlying profit before tax increased 33.4% to $30.24 million, excluding a capital sale from the previous period
  • $23.1 million worth of full-year reported profits, a 20.7% increase
  • $43.4 million worth of cash in the bank and no debt
  • A 6-cent final dividend, bringing its total FY20 dividends to 12 cents per share

Pro Medicus' growth was driven by increases in its transaction revenues in North America and Australia.

However, the company's European revenue dropped, mainly because the company completed a $3 million one-off capital sale to the German government in FY19.

The Pro Medicus share price dipped on the back of its FY20 results. It ended the day 2.5% lower than where it started.

What's driven the Pro Medicus share price since?

Pro Medicus has been performing brilliantly on the ASX since it dropped its FY20 earnings.

It has announced a seven-year contract and research agreement with NYU Langone Health, a $10 million deal with LMU Klinikum, a five-year contract with MedStar Health, and a seven-year contract with Intermountain Healthcare.

Additionally, Pro Medicus announced a new on-market share buyback in April. The buyback will see it pocketing 10% of its issued securities.

With so much productivity evidenced in the company's market releases during FY21, investors may be on the edge of their seat waiting to see how the Pro Medicus share price responds to its imminent results.

At its current share price, Pro Medicus has a market capitalisation of around $5.92 billion. It has approximately 104 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »